RBC Capital analyst Brian Abrahams downgraded Sage Therapeutics to Sector Perform from Outperform with a price target of $25, down from $71. Zuranolone may have received approval in postpartum depression, but the Complete Response Letter with requirement for additional clinical work places at “considerable risk” the drug’s future opportunity in the much more sizable major depressive disorder indication, the analyst tells investors in a research note. The firm expects “meaningful stock downside on this setback” and sees fair value at $25 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Sage (NASDAQ:SAGE) Plummets On FDA Snub for Zuranolone in Major Depression Disorder
- Sage Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Sage, Biogen receive CRL for zuranolone in major depressive disorder
- SAGE Upcoming Earnings Report: What to Expect?
- FDA approves Zurzuvae for postpartum depression